Hormonal

Kisspeptin

Reproductive hormone signaling peptide

Investigational; no FDA-approved kisspeptin-10 product identified.

What does it do?

Reproductive hormone

Study

Human studies measure LH, FSH and testosterone responses; fertility and symptom benefits cannot be assumed.1 2

Community hormone support

Community

Community summaries mix kisspeptin fragments, limiting interpretation of a KP-10-specific schedule.7

Molecular information

Amino-acid sequence

10 residues · N → C4

Length10 amino acids

Molecular weight · Da1302.4 Da

Molecular formulaC₆₃H₈₃N₁₇O₁₄4

C-terminal amide.

KP-10 is distinct from kisspeptin-54 and other analogs; molecular values exclude salt counterions.

Pharmacokinetics

Data shown

Human data

Reported half-lifeAbout 3.8 minutes in men5

Route / formulationIntravenous infusion, after cessation

Elapsed time 3.8 min

50%of reference level

Illustrative model using reported human data.

About 3% remaining after 19 min

Five half-lives in this simplified model. This is not a prediction of when effects stop.

About this estimate

Kisspeptin immunoreactivity declined with mean half-lives of 3.8±0.3 minutes in men and 4.1±0.4 minutes in follicular/preovulatory women (SEM). The plotted value uses the male mean; this is not a subcutaneous absorption model.

Population: Healthy men and women

100 × 2^{−time / half-life}. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.

What to expect

Study outcomes

Hormone responses depend on context

Small studies increased LH in men; the sexual-dimorphism study found no significant reproductive-hormone increase in follicular-phase women across its tested KP-10 schedules.1 2

Reported timelines

Reference & community

2–5 h; 12–14 h

Source-reported LH peak and return.29

Days 1–2; weeks 2–4

Reported sex-hormone then libido changes; context/isoform dependent.29

These are reported timelines, not a prediction of your response.

Doses & schedules

Route

Scroll to compare all columns →

One row for each documented route and dose or dose range
Route	Dose	Frequency	Goal / evidence	Duration	References
IVIntravenous	4 μg/kg/hour	Continuous infusion	Measure LH and testosterone responsesHealthy men; four in the prolonged-infusion groupHuman study	22.5 hours	1
Population Healthy men; four in the prolonged-infusion group Context Physiological hormone endpoints, not a validated fertility or libido treatment.
SubQSubcutaneous infusion	150 nmol/hour during infusion	8 hours on, 16 hours off each day	Sustained gonadotropin secretionHealthy men; intermittent-infusion study armHuman study	12 days	6
Population Healthy men; intermittent-infusion study arm Context Research infusion regimen; not a bolus-injection or fertility-treatment recommendation.
SubQ	100-200 mcg	Single dose or 2-3x/week	Gonadotropin stimulationReference report	2-4 weeks	29
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source's blanket daily-use prohibition and 2–3× weekly limit are not validated universal protocols. Interaction labels are reference claims. Source tabs Injectable
SubQSubQ (KP-54)	0.4-1.0 nmol/kg (50-150 mcg)	As directed by physician	Fertility supportReference report	2-4 weeks	29
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source's blanket daily-use prohibition and 2–3× weekly limit are not validated universal protocols. Interaction labels are reference claims. Source tabs Injectable
IVIV infusion	1 nmol/kg/h	75 min IV infusion (clinical)	Sexual functionReference report	2-4 weeks	29
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source's blanket daily-use prohibition and 2–3× weekly limit are not validated universal protocols. Interaction labels are reference claims. Source tabs Injectable
SubQSubcutaneous	0.3-10 nmol/kg	Variable by protocol	Research protocolsReference report	2-4 weeks	29
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source's blanket daily-use prohibition and 2–3× weekly limit are not validated universal protocols. Interaction labels are reference claims. Source route wording IV bolus or SubQ Source tabs Injectable
IVIntravenous	0.3-10 nmol/kg	Variable by protocol	Research protocolsReference report	2-4 weeks	29
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source's blanket daily-use prohibition and 2–3× weekly limit are not validated universal protocols. Interaction labels are reference claims. Source route wording IV bolus or SubQ Source tabs Injectable

Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.

Cycles & timing

Reference reports29

Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.

Injectable

Use period: 2-4 weeks
Break: 4+ weeks to prevent desensitization

Reported timing

Morning preferred for natural hormone rhythm

Side effects & safety

Limited safety evidence

FDA identifies little or no safety information for proposed compounded routes.

Immune and impurity concerns

FDA flags possible immunogenicity and difficulties characterizing peptide impurities.

Population limits

Brief hormone studies in healthy adults do not establish reproductive, pregnancy or long-term safety.

Additional reported cautions

Reference reports29

Hormonal and vascular effects

Repeated stimulation may desensitize responses; exact safe frequency unestablished. Heart disease warrants review.

Stop symptoms

Pelvic pain/bloating, chest pain, severe headache, mood changes, infection or precocious puberty signs.

Pregnancy/lactation

Safety unestablished.

Not a complete safety screen. Discuss health decisions with a qualified clinician.

Combinations & interactions

5 entries

Check cautions and reported pairings. A compatibility claim does not establish that a combination is safe.

GnRH

Unverified pairing

Upstream/downstream pathway relationship.29

Reference report · Pep-Pedia label: Synergistic

hCG

Unverified pairing

Clinical IVF comparison; not interchangeable self-use.29

Reference report · Evidence context: Alternative

Testosterone

Unverified pairing

Feedback-dependent; combination unvalidated.29

Reference report · Pep-Pedia label: Compatible

Estrogen

Unverified pairing

Sex-steroid feedback matters.29

Reference report · Pep-Pedia label: Compatible

Fertility hormones and other endocrine medicines

Not established

These small physiology studies do not establish routine combination safety or interchangeable effects with kisspeptin-54.2

Research context

Reconstitution calculator

Enter your peptide amount and container size. Get a volume and a simple measurement scale.

1How much peptide do you have?

Total labeled amount of Kisspeptin.

2How much can your container hold?

Usable capacity of the destination vial or pen cartridge.

Measure with

1 dial unit = 0.01 mL on the documented V2 model. Confirm your pen’s scale.

Vial examples & blend contents Kisspeptin

Peptide reference

Listed amounts are packaging examples. Check your actual label.

Suggested final volume mL

Estimated water to add≈ mL

For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.

1 pen unit (one dial step)=

Measurement scale Conversions, not recommended doses
Pen units	Amount	Volume

Other simple scales

Convert a specific amount

Enter an amount to calculate its volume and device setting.

Amount to measure

Measuring-tool capacity

Calculation & assumptions

The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.

The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.

V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗

Reconstitution

Study formulation only

The human study used a controlled infusion preparation, not a universal research-vial recipe.5

Documented preparation

For infusion, KP-10 was dissolved in saline containing 5% v/v Gelofusine. This study vehicle does not establish bacteriostatic-water compatibility or a home-use storage period.5

Reference preparation details

Reported handling information, not a validated formulation or instruction to prepare an injectable product.

Injectable

The source reports BAC water and an optional acidification suggestion when dissolution is incomplete.

Solvents mentioned: Bacteriostatic water
Reported parameters: It names 0.6% acetic acid for that suggestion without quantifying a validated final formulation. · Reported 2–8°C intervals differ: KP-10, 7 days; KP-54, up to 14 days.

The source describes gentle mixing and avoiding vigorous shaking.

KP-10 and KP-54 are different compounds; their stability claims must not be interchanged.

Appearance & documentation

Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.

Reported appearanceWhite, Fluffy PowderReported appearanceClear Solution After ReconstitutionReported appearanceProtected from LightReported variationSlight CompactionReported concernDiscoloration or YellowingReported concernCloudy After Reconstitution

Vial sizes

5mg8

10mg8

Packaging examples, not a market survey. Approved and research products are not interchangeable.

Storage after mixing

Reconstituted research vials

Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.

Injectable

Unverified report29

2–8°C · 7–14 days

Storage notes

Injectable

Fridge 2-8°C, use within 7-14 days

Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.

Pen & syringe measurements

Device units measure volume. Concentration determines the amount in mg.

Open calculator ↗

V2 peptide pen

1 notch = 0.01 mL

Documented 1-unit V2 models

One dial increment: 1 unit
Cartridge capacity: 3 mL
Maximum setting: 60 units · 0.60 mL

Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.

U-100 syringe

1 unit = 0.01 mL

100 units = 1 mL

10 units: 0.10 mL
30-unit capacity: 0.30 mL
50 / 100-unit capacity: 0.50 / 1 mL

Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.

Other measuring tools

Use the mL scale

mL syringes and calibrated pipettes

0.01 mL: 10 µL
0.10 mL: 100 µL
Amount: mL × mg/mL

Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.

3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.

Device references

AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.

Evidence limits

View findings →

Whether chronic use improves clinically meaningful fertility or sexual-health outcomes.1

6 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.

Evidence definitions →

Research findings

Limited human data

Source context

Source's blanket daily-use prohibition and 2–3× weekly limit are not validated universal protocols. Interaction labels are reference claims.

Compound identity & other names

Kisspeptin-10 stimulates reproductive-hormone signaling in small human physiology studies. Changes in LH and testosterone are not proof of improved fertility, symptoms, or long-term health. Kisspeptin-54 is a different fragment.

Other names: KP-10 · KP10 · kisspeptin · metastin fragment · Kisspeptin-10 · KP-54

Investigational; no FDA-approved kisspeptin-10 product identified.

Human kisspeptin-10: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2.4

Pep-Pedia identity record

10-54 amino acids · 1,213.42 Da (KP-10) / 6,087 Da (KP-54)

Kisspeptin-10: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 | Kisspeptin-54: 54 amino acid C-terminal fragment

Reference description; checked chemical identity takes precedence when available.29

How it may work

KISS1R stimulation activates GnRH, then LH/FSH and gonadal hormones.29

A measurable LH response in small male cohorts

In six healthy men, 1 μg/kg intravenously increased mean LH from 4.1 to 12.4 IU/L at 30 minutes. Four men receiving a prolonged infusion had higher LH and testosterone; these were hormone endpoints.

Responses differ by reproductive context

A separate study with four or five people per group found hormone responses in men, but no gonadotropin rise in women during the follicular phase at the studied doses/routes.

New human KP-10 infusion study

In healthy men, intermittent subcutaneous KP-10 infusion sustained LH and FSH stimulation for 12 days. Continuous infusion did not sustain the same gonadotropin response, showing that delivery pattern matters.

Research areas and evidence gaps

Reproductive hormone research. Human studies measure LH, FSH and testosterone responses; fertility and symptom benefits cannot be assumed.1 2

Whether chronic use improves clinically meaningful fertility or sexual-health outcomes.
Generalizability from healthy volunteers to hormonal disorders.
KP-54 findings cannot be assigned to KP-10 without checking the actual study material.
KP-10 and KP-54 differ; the 2026 subcutaneous study concerns KP-10, while several catalog references concern KP-54.

Additional uses listed by Pep-Pedia

Reproductive disorders. Research in hypogonadism, hypothalamic amenorrhea and IVF triggering; much clinical evidence concerns kisspeptin-54.29

Sexual desire. Human brain-response/arousal studies, not established routine therapy.29

Metabolism and body composition. Animal energy/glucose findings.29

Community reports Unvalidated

PepPedia combines multiple kisspeptin fragments and discusses fertility and libido; its fragment-specific claims require careful reading.7

PepPedia's editorial protocol summary, not measured community consensus. Benefits, product identity, and safety are not independently verified; these reported practices are not recommendations. The cited row cannot establish a KP-10-specific regimen.

Search coverage and review status

Added a randomized 2026 KP-10 infusion study. KP-54 bibliography and prior intravenous PK remain formulation specific.

Checked: 2026-10-12
Search: "kisspeptin" "2026" trial; kisspeptin-10 subcutaneous 12 days
Catalog: Pep-Pedia ↗ · 19 listed references retained

Targeted search and selected primary-source checks, not an exhaustive systematic review.
Preserved bibliography entries marked unreviewed have not had their findings independently verified.

AI-prepared summaries. Independent medical editorial review is pending.

Community poll 10 topics · Pep-Pedia snapshot

Voluntary, unverified reports. These percentages do not measure effectiveness or safety.

Topic

Primary goal

General wellness30%

Muscle growth7%

Other: Libido6%

Other: Fertility6%

Other: Libido 6%

The source hides 31 additional categories. Their labels and percentages are unavailable.

Number of responses to this question: not disclosed.

Source & limitations

The source displays “903 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.

Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
This is a dated snapshot, not a live survey or current recommendation.

References

Original sources and review status. Open a reference to read its summary.

29 sources

1Kisspeptin-10 stimulates LH and increases pulse frequencyTrial · 2011 · pubmed.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

Small healthy-male cohorts showed acute LH stimulation and higher testosterone during continuous infusion; no fertility endpoint was established.

A measurable LH response in small male cohorts

In six healthy men, 1 μg/kg intravenously increased mean LH from 4.1 to 12.4 IU/L at 30 minutes. Four men receiving a prolonged infusion had higher LH and testosterone; these were hormone endpoints.

Original source

2Sex differences in hormone responses to kisspeptin-10Trial · 2011 · pubmed.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

Small cohorts showed context-dependent responses, including no gonadotropin change in follicular-phase women under the tested conditions.

Responses differ by reproductive context

A separate study with four or five people per group found hormone responses in men, but no gonadotropin rise in women during the follicular phase at the studied doses/routes.

Original source

3FDA: compounding safety concernsRegulator · 2026 · fda.govPrimary source checked

AI-PREPARED SUMMARY

Regulatory safety assessment.

Original source

4PubChem: Kisspeptin-10, CID 25240297Registry · 2026 · pubchem.ncbi.nlm.nih.govPrimary source checked

AI-PREPARED SUMMARY

Defines the human amidated decapeptide, formula and average molecular weight.

Original source

5Jayasena et al.: KP-10 sex differences and pharmacokinetics — full paperTrial · 2011 · scispace.comAbstract checked

AI-PREPARED SUMMARY

Full text of PMID 21976724: infusion vehicle and human immunoreactivity half-lives after stopping IV KP-10. Hormone responses vary by sex and cycle phase.

Original source

6Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy menTrial · 2026 · pubmed.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

A randomized placebo-controlled study found sustained gonadotropin stimulation during intermittent subcutaneous KP-10 infusion for 12 days. Continuous infusion showed a different response pattern.

New human KP-10 infusion study

Additional research · Checked 2026-10-12

Original source

7PepPedia: reported practices (accessed October 12, 2026)Community · 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Secondary editorial account of discussed practices; not a clinical trial or representative survey.

Original source

8Research catalog: labeled quantitiesCatalog · 2026 · apexlab.orgCatalog checked

AI-PREPARED SUMMARY

Lists 5 mg and 10 mg configurations. Quantity examples only; vendor quality and suitability are not endorsed.

Original source

9Intranasal Kisspeptin Administration (2025)Reference · Accessed 2026 · doi.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Intranasal KP-54 stimulated gonadotropins in several human groups. The tested compound was kisspeptin-54, not kisspeptin-10.

Reported population / model
Humans

Reported study details
12.8 nmol/kg intranasal KP-54 · Healthy adults and HA patients

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

10Kisspeptin for Hypoactive Sexual Desire Disorder in Men (2023)Reference · Accessed 2026 · doi.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The male HSDD trial reported brain-response changes and up to 56% greater penile tumescence; the specific kisspeptin isoform must be distinguished.

Reported population / model
Humans

Reported study details
32 men with HSDD · 1 nmol/kg/h IV infusion · 75 minutes · RCT

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

11Kisspeptin for HSDD in Women (2022)Reference · Accessed 2026 · doi.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Women showed changes in attraction-related brain processing and exploratory self-report measures; this does not establish routine treatment efficacy.

Reported population / model
Humans

Reported study details
32 women with HSDD · 1 nmol/kg/h IV infusion · 75 minutes · RCT

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

12Kisspeptin as IVF Ovulation Trigger (2017)Reference · Accessed 2026 · doi.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The IVF report concerns KP-54, with 45% live births and no moderate/severe OHSS in the described study; KP-10 cannot inherit those results.

Reported population / model
Humans

Reported study details
Multiple doses tested · Subcutaneous KP-54 · Clinical trial

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

13Kisspeptin Cardiovascular Effects Study (2017)Reference · Accessed 2026 · doi.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: KP-10 constricted vessels and increased atherosclerotic lesions in mice; a receptor antagonist reversed the experimental effects.

Reported population / model
Human vessels and Apoe-/- mice

Reported study details
4-week KP-10 infusion · Ex vivo studies

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

14Kisspeptin Effects on Metabolism and Obesity (2014)Reference · Accessed 2026 · doi.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Female receptor-knockout mice became heavier despite eating less, with lower energy use and impaired glucose tolerance.

Reported population / model
Mice

Reported study details
Kiss1r knockout models · Long-term observation

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

15Discovery of Kisspeptin-GPR54 in Reproduction (2003)Reference · Accessed 2026 · doi.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Loss-of-function GPR54 variants were linked to pubertal failure and hypogonadotropic hypogonadism; genetic necessity does not define a treatment regimen.

Reported population / model
Humans

Reported study details
Genetic studies · Inactivating GPR54 mutations identified

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

16Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With HSDDReference · Accessed 2026 · doi.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The male HSDD trial reported brain-response changes and up to 56% greater penile tumescence; the specific kisspeptin isoform must be distinguished.

Reported population / model
Humans

Reported study details
32 men with HSDD · 1 nmol/kg/h IV infusion · 75 minutes · RCT

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

17Effects of Kisspeptin Administration in Women With HSDDReference · Accessed 2026 · doi.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Women showed changes in attraction-related brain processing and exploratory self-report measures; this does not establish routine treatment efficacy.

Reported population / model
Humans

Reported study details
32 women with HSDD · 1 nmol/kg/h IV infusion · 75 minutes · RCT

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

18Kisspeptin-54 triggers egg maturation in women undergoing IVFReference · Accessed 2026 · doi.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The IVF report concerns KP-54, with 45% live births and no moderate/severe OHSS in the described study; KP-10 cannot inherit those results.

Reported population / model
Humans

Reported study details
Multiple doses tested · Subcutaneous KP-54 · Clinical trial

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

19Use of kisspeptin to trigger oocyte maturation during IVFReference · Accessed 2026 · doi.orgLinked reference · Not independently reviewed

REFERENCE NOTE

Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source

20Hypogonadotropic hypogonadism due to loss of function of KiSS1-derived peptide receptor GPR54Reference · Accessed 2026 · doi.orgLinked reference · Not independently reviewed

REFERENCE NOTE

Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source

21The GPR54 gene as a regulator of pubertyReference · Accessed 2026 · doi.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Loss-of-function GPR54 variants were linked to pubertal failure and hypogonadotropic hypogonadism; genetic necessity does not define a treatment regimen.

Reported population / model
Humans

Reported study details
Genetic studies · Inactivating GPR54 mutations identified

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

22Impaired kisspeptin signaling decreases metabolism and promotes glucose intolerance and obesityReference · Accessed 2026 · doi.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Female receptor-knockout mice became heavier despite eating less, with lower energy use and impaired glucose tolerance.

Reported population / model
Mice

Reported study details
Kiss1r knockout models · Long-term observation

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

23Kisspeptins: multifunctional system in reproduction cancer and cardiovascular functionReference · Accessed 2026 · doi.orgLinked reference · Not independently reviewed

REFERENCE NOTE

Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source

24KISS1/KISS1R in cancer: Friend or foe?Reference · Accessed 2026 · doi.orgLinked reference · Not independently reviewed

REFERENCE NOTE

Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source

25Kisspeptin-10 induces atherosclerotic plaque progression and instabilityReference · Accessed 2026 · doi.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: KP-10 constricted vessels and increased atherosclerotic lesions in mice; a receptor antagonist reversed the experimental effects.

Reported population / model
Human vessels and Apoe-/- mice

Reported study details
4-week KP-10 infusion · Ex vivo studies

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

26Emerging Therapeutic Potential of Kisspeptin and Neurokinin BReference · Accessed 2026 · doi.orgLinked reference · Not independently reviewed

REFERENCE NOTE

Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source

27Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humansReference · Accessed 2026 · doi.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Intranasal KP-54 stimulated gonadotropins in several human groups. The tested compound was kisspeptin-54, not kisspeptin-10.

Reported population / model
Humans

Reported study details
12.8 nmol/kg intranasal KP-54 · Healthy adults and HA patients

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

28Pep-Pedia: Kisspeptin — reported pharmacokineticsReference estimate; not independently verified human PKCommunity · 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Lists a half-life of 28 min and a peak time of 3 min. Stated attribution: Dhillo et al. 2005 J Clin Endocrinol Metab 90(12):6609-6615. The cited 2005 Dhillo research concerns kisspeptin-54, not the kisspeptin-10 formulation in this profile. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.

Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12

Original source

29Pep-Pedia: Kisspeptin — route-specific referenceReference page checked; underlying claims require separate verification.Community · Checked 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.

Content coverage audit · Checked 2026-10-12

Original source

What does it do?

Reproductive hormone

Community hormone support

Molecular information

Amino-acid sequence

Pharmacokinetics

About this estimate

About this estimate

What to expect

Study outcomes

Hormone responses depend on context

Reported timelines

2–5 h; 12–14 h

Days 1–2; weeks 2–4

Doses & schedules

Cycles & timing

Injectable

Reported timing

Side effects & safety

Limited safety evidence

Immune and impurity concerns

Population limits

Additional reported cautions

Hormonal and vascular effects

Stop symptoms

Pregnancy/lactation

Combinations & interactions

GnRH

hCG

Testosterone

Estrogen

Fertility hormones and other endocrine medicines

Reconstitution calculator

Ingredients per unit

Reconstitution

Documented preparation

Reference preparation details

Injectable

Appearance & documentation

Vial sizes

Storage after mixing

Reconstituted research vials

Injectable

Storage notes

Pen & syringe measurements

1 notch = 0.01 mL

1 unit = 0.01 mL

Use the mL scale

Evidence limits

Research findings

Source context

Pep-Pedia identity record

How it may work

A measurable LH response in small male cohorts

Responses differ by reproductive context

New human KP-10 infusion study

Research areas and evidence gaps

Additional uses listed by Pep-Pedia

Community reports Unvalidated

Experience

Duration of use

Age range

Gender

Primary goal

Effectiveness

Side effects

Dosage frequency

Would recommend

How discovered

References

Related profiles